Authors
Loading...
Cross-sectional study evaluates IFI44L promoter hypomethylation as a biomarker for SLE diagnosis and monitoring, suggesting its clinical relevance.
Zhang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: